Equity in Neuroscience and Alzheimer’s Clinical Trials (ENACT) Act (S. 1548 / H.R. 3085), bills sponsored by the Alzheimer's Association and included in the end-of-year Congressional omnibus funding bill, is designed to expand education and outreach to underrepresented populations, encourage the diversity of clinical trial staff, and reduce participation burden, among other priorities. This legislation will enable the involvement of adults with intellectual disability, their families, and advocates to be eventually included in upcoming clinical trials of emerging pharmaceuticals for the treatment of Alzheimer's disease.
